Compare HTGC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | LQDA |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2005 | 2018 |
| Metric | HTGC | LQDA |
|---|---|---|
| Price | $16.60 | $39.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $21.00 | ★ $38.60 |
| AVG Volume (30 Days) | ★ 1.9M | 1.9M |
| Earning Date | 02-12-2026 | 03-18-2026 |
| Dividend Yield | ★ 11.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $516,847,000.00 | $69,216,000.00 |
| Revenue This Year | $10.13 | $993.31 |
| Revenue Next Year | $9.62 | $219.14 |
| P/E Ratio | $9.58 | ★ N/A |
| Revenue Growth | 4.54 | ★ 343.41 |
| 52 Week Low | $15.65 | $11.26 |
| 52 Week High | $22.04 | $46.67 |
| Indicator | HTGC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 47.22 |
| Support Level | $16.22 | $38.88 |
| Resistance Level | $17.00 | $46.67 |
| Average True Range (ATR) | 0.38 | 2.44 |
| MACD | -0.16 | -0.72 |
| Stochastic Oscillator | 15.12 | 2.70 |
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.